Lucentis

Active Ingredient(s): Ranibizumab
FDA Approved: * June 30, 2006
Pharm Company: * GENENTECH
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lucentis Overview

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis,[2] under the brand name Lucentis. Contents 1 Medical us...

Read more Lucentis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ranibizumab

Recent Lucentis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lucentis: (2 results)

Sorted by National Drug Code

• 50242-080 Lucentis 10 mg/ml Intravitreal Injection, Solution by Genentech, Inc.
• 50242-082 Lucentis 6 mg/ml Intravitreal Injection, Solution by Genentech, Inc.

Other drugs which contain Ranibizumab or a similar ingredient: (1 result)

• RANIBIZUMAB

Related Lucentis Topics: